Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 139K, Worst grade adverse event for individual patients that occurred within the first twelve weeks of treatment (induction dose-limiting toxicity period). Adverse events recorded multiple times for any patient are reported only once according to the worst grade.
Authors: F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie-Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, George F. Murphy, Scott Rodig, Elsa F. Velazquez, Martin C. Mihm, Sara Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil Ramaiya, Annick D. Van den Abbeele, Maria Gargano, David McDermott
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362539950